Validation of the BARD scoring system for fibrosis detection in nonalcoholic fatty liver disease

验证BARD评分系统在非酒精性脂肪性肝病纤维化检测中的应用

阅读:1

Abstract

The diagnostic performance of the BARD scoring system in detecting significant fibrosis (≥F2) among Bangladeshi patients with biopsy-proven NAFLD is of interest. A cross-sectional study was conducted on 40 adult NAFLD patients at Bangladesh Medical University, Dhaka. Liver fibrosis was staged histologically from biopsy specimens. The BARD score was calculated for each patient and its diagnostic accuracy was evaluated using sensitivity, specificity, predictive values and ROC curve analysis. Clinical and biochemical predictors of fibrosis were also assessed. Among the cohort, 45% had significant fibrosis (F2-F4). The BARD score demonstrated a sensitivity of 83.3%, specificity of 86.4%, positive predictive value of 83.3%, negative predictive value of 86.4% and an AUROC of 0.908 (p < 0.001). A strong positive correlation was observed between BARD score and fibrosis stage (r = 0.736). Multivariate analysis identified BMI ≥28 kg/m(2) as an independent predictor of significant fibrosis (OR 17.53, p = 0.022). The BARD score is a reliable noninvasive tool for identifying significant liver fibrosis in Bangladeshi NAFLD patients, facilitating early risk stratification and management in resource-limited settings.

特别声明

1、本页面内容包含部分的内容是基于公开信息的合理引用;引用内容仅为补充信息,不代表本站立场。

2、若认为本页面引用内容涉及侵权,请及时与本站联系,我们将第一时间处理。

3、其他媒体/个人如需使用本页面原创内容,需注明“来源:[生知库]”并获得授权;使用引用内容的,需自行联系原作者获得许可。

4、投稿及合作请联系:info@biocloudy.com。